www.public4you.fora.pl

njlpkhgea

,[link widoczny dla zalogowanych]
Are two immunomodulating agents assisted LAK cell killing of laryngeal cancer cells

Have a certain effect. However, due to certain deficiencies of the therapy, such as the source of the lack of LAK cell precursors, 1L-2 half-life is short, expensive,[link widoczny dla zalogowanych], high-dose intravenous infusion can produce severe side effects, to some extent limited in the clinical treatment II a 2/LAK application. IL-2 is a kind of immune response play a central regulatory role of cytokines and other immune modulators that have a close relationship between: If mutual induced, receptor regulation, biological activity or inhibition of synergies, etc.] . Many studies have found that IL-2 and interferon (IFN) or tumor necrosis factor (TNF) have synergistic anti-tumor effect. Our results show that,[link widoczny dla zalogowanych], MPS, and c monoclonal antibody could enhance the LAK cells in vitro amplification and killing capacity,[link widoczny dla zalogowanych], MPS, or CD synergistic IL-2 monoclonal antibody induced LAK cells in cell culture expansion of early and late times are significantly higher than that with IL-2 group and the control group, the difference was significant. Immunomodulator MPS and CD. Monoclonal antibodies to promote proliferation and LAK cells in the mechanism of killing tumor cells is not clear. Some scholars believe that the CD monoclonal antibodies specifically bind to T lymphocytes through surface molecules on T c and the function of lymphocytes from the two-way adjustment; amount of cD3 monoclonal antibodies can activate T lymphocytes to promote IL-2,[link widoczny dla zalogowanych],4, A 7 6 and IFN and other cytokine production and 1L-2 receptor, receptor expression of twist in the IL2 synergy of production may promote cell proliferation and cytotoxicity. MPS is a non-pathogenic mycobacteria from the extract of the molecular weight of 9,000 ~ 11,000 of the polysaccharides. On human immune function of a clear regulatory role, with activated macrophages and killing activity of phagocytic cells, NK cell cytotoxic activity and can promote cell garden IFN-Y, IL-2 production. Since cell proliferation stimulated significantly improve the GM-CSF (granulocyte monocyte colony stimulating factor a) Immunomodulatory effects of activity level 0. It is worth noting that the MPS and immunomodulator CD. Although the monoclonal antibody could improve the human LAK cells in vitro anti-proliferation and the activity of laryngeal carcinoma cells, but the MPS can significantly reduce the amount of IL-2, only IL-2 other groups one-fifth of the amount, and the MPS has governance as a product in clinical testing of the use of MPS, and IL-2/LAK expected to adoptive immunotherapy in patients with advanced cancer will have a clinical application.